다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Indaptus Therapeutics Inc (INDP)
Indaptus Therapeutics Inc (INDP) 뉴스

INDP

Indaptus Therapeutics (INDP)

Indaptus Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:INDP

1 2 3 4 5 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/22	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/05/22	21:00	GlobeNewswire Inc.	Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/05/08	21:06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/05/08	21:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/05/08	21:00	GlobeNewswire Inc.	Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/04/11	20:30	GlobeNewswire Inc.	Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/28	21:00	GlobeNewswire Inc.	Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/25	21:30	GlobeNewswire Inc.	Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/18	21:00	GlobeNewswire Inc.	Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/13	20:30	GlobeNewswire Inc.	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/05	01:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/04	21:30	GlobeNewswire Inc.	Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/02/15	22:00	GlobeNewswire Inc.	Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/02/08	22:00	GlobeNewswire Inc.	Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/01/24	06:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/01/24	06:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/01/04	22:00	GlobeNewswire Inc.	European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/11/07	06:06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/11/07	06:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/11/07	06:01	GlobeNewswire Inc.	Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/11/06	22:13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/11/06	22:00	GlobeNewswire Inc.	Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/10/31	22:12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/10/31	22:01	GlobeNewswire Inc.	Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/09/27	21:00	GlobeNewswire Inc.	Indaptus Therapeutics to Present at the LD Micro Main Event XVI	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/09/26	21:00	GlobeNewswire Inc.	Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/09/19	21:00	GlobeNewswire Inc.	Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/09/06	21:05	GlobeNewswire Inc.	Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/08/17	07:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/08/14	21:15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:INDP	Indaptus Therapeutics Inc

검색 관련기사 보기:NASDAQ:INDP

1 2 3 4 5 다음 >>

Health Care Select Sector

American Express

Energy Select Sector SPDR

Verizon Communications

Financial Select Sector

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관